Patents Represented by Attorney Melya J. Hughes
-
Patent number: 5965543Abstract: Recombinant polynucleotides have expression control sequences that have a senescence responsive element and a minimal promoter, and which are operatively linked to a heterologous nucleotide sequence. The molecules are useful for achieving high levels of expression of genes in senescent cells. Methods of inhibiting expression of genes in senescent cells also are provided.Type: GrantFiled: April 17, 1997Date of Patent: October 12, 1999Assignee: Geron CorporationInventors: Judith Campisi, Alessandro Testori
-
Patent number: 5891639Abstract: Telomerase activity in a sample can be measured using a two reaction protocol. The first reaction involves the formation of telomerase substrate extension products from a telomerase substrate. The second reaction involves replication of the telomerase substrate extension products and/or amplification of signal generated by a bound probe. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose a disease or other conditions of medical interest, as well as the course of disease progression or remission in a patient.Type: GrantFiled: June 18, 1998Date of Patent: April 6, 1999Assignee: Geron CorporationInventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
-
Patent number: 5863726Abstract: Telomerase activity in a sample can be measured using a two reaction protocol. The first reaction involves the formation of telomerase substrate extension products from a telomerase substrate. The second reaction involves replication of the telomerase substrate extension products and/or amplification of signal generated by a bound probe. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose a disease or other conditions of medical interest, as well as the course of disease progression or remission in a patient.Type: GrantFiled: April 12, 1996Date of Patent: January 26, 1999Assignee: Geron CorporationInventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
-
Patent number: 5840490Abstract: Methods for detecting hematologic and colorectal malignancies are provided comprising: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the presence of telomerase activity with the presence of cancer cells. A method for staging leukemia is also provided comprising analyzing a blood or bone marrow sample for telomerase activity, correlating the activity with a standard level of telomerase activity, and correlating a low telomerase activity with early stage leukemia.Type: GrantFiled: June 7, 1995Date of Patent: November 24, 1998Assignee: McMaster UniversityInventors: Silvia Bacchetti, Christopher M. Counter, Brian Leber, Calvin Bruce Harley
-
Patent number: 5837453Abstract: Telomerase activity in a sample can be measured using a two reaction protocol involving telomerase substrate and primer extension steps. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose the course of disease progression in a patient.Type: GrantFiled: June 7, 1995Date of Patent: November 17, 1998Assignee: Geron CorporationInventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
-
Patent number: 5804380Abstract: Telomerase activity in a sample can be measured using a two reaction protocol. The first reaction involves the formation of telomerase substrate extension products from a telomerase substrate. The second reaction involves replication of the telomerase substrate extension products and/or amplification of signal generated by a bound probe. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose a disease or other conditions of medical interest, as well as the course of disease progression or remission in a patient.Type: GrantFiled: April 15, 1996Date of Patent: September 8, 1998Assignee: Geron CorporationInventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
-
Patent number: 5705342Abstract: The invention provides compositions and methods for screening for agents which are modulators of bcl-2 function and can modulate bcl-2-mediated apoptosis and/or modulate neoplastic and immune conditions dependent upon bcl-2 function. The invention also provides a composition comprising a substantially pure protein complex comprising a R-ras polypeptide and a bcl-2 polypeptide.Type: GrantFiled: June 7, 1995Date of Patent: January 6, 1998Assignee: Onyx Pharmaceuticals, Inc.Inventors: James R. Bischoff, Maria Jose Fernandez-Sarabia
-
Patent number: 5693474Abstract: A method for predicting tumor progression and prognosing cancer comprises: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the activity with a standard level of telomerase activity; and (d) correlating a high telomerase activity with an indication of unfavorable prognosis and a low telomerase activity with a favorable prognosis.Type: GrantFiled: June 7, 1995Date of Patent: December 2, 1997Assignee: Board of Regents, University of Texas SystemInventors: Jerry Shay, Michael David West, Woodring E. Wright
-
Patent number: 5639613Abstract: A method for predicting tumor progression and prognosing cancer comprises: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the activity with a standard level of telomerase activity; and (d) correlating a high telomerase activity with an indication of unfavorable prognosis and a low telomerase activity with a favorable prognosis.Type: GrantFiled: April 18, 1995Date of Patent: June 17, 1997Assignee: Board of Regents, University of Texas SystemInventors: Jerry Shay, Michael David West, Woodring E. Wright